Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Translating Cell and Gene biopharmaceutical products for health and market impact Product scaling from clinical to marketplace: Lessons learned and future outlook.

Bak A, Friis KP, Wu Y, Ho RJ.

J Pharm Sci. 2019 May 28. pii: S0022-3549(19)30360-0. doi: 10.1016/j.xphs.2019.05.027. [Epub ahead of print]

PMID:
31150697
2.

Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.

Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD, Ho RJY.

J Pharm Sci. 2018 Dec;107(12):3153-3162. doi: 10.1016/j.xphs.2018.07.032. Epub 2018 Aug 16.

3.

Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.

Koehn J, Iwamoto JF, Kraft JC, McConnachie LA, Collier AC, Ho RJY.

AIDS. 2018 Nov 13;32(17):2463-2467. doi: 10.1097/QAD.0000000000001969.

PMID:
30102655
4.

Conjugation of Phthalocyanine Photosensitizer with Poly(amidoamine) Dendrimer: Improved Solubility, Disaggregation and Photoactivity Against HepG2 Cells.

Jiang Z, Ye J, Yang J, Wang J, Jia L, Ho RJ.

Curr Cancer Drug Targets. 2019;19(4):312-320. doi: 10.2174/1568009618666180706164046.

PMID:
29984658
5.

Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Gao Y, Kraft JC, Yu D, Ho RJY.

Eur J Pharm Biopharm. 2019 May;138:75-91. doi: 10.1016/j.ejpb.2018.04.014. Epub 2018 Apr 17. Review.

PMID:
29678735
6.

Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII.

Lu L, Ding Y, Zhang Y, Ho RJ, Zhao Y, Zhang T, Guo C.

Int J Nanomedicine. 2018 Mar 29;13:1927-1944. doi: 10.2147/IJN.S153107. eCollection 2018.

7.

Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

McConnachie LA, Kinman LM, Koehn J, Kraft JC, Lane S, Lee W, Collier AC, Ho RJY.

J Pharm Sci. 2018 Jul;107(7):1787-1790. doi: 10.1016/j.xphs.2018.03.005. Epub 2018 Mar 13.

PMID:
29548975
8.

Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Sun J, Collier AC, Collins C, Shen DD, Ho RJY.

J Control Release. 2018 Apr 10;275:229-241. doi: 10.1016/j.jconrel.2018.02.003. Epub 2018 Feb 10.

9.

Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities.

Kraft JC, Treuting PM, Ho RJY.

J Drug Target. 2018 Jun - Jul;26(5-6):494-504. doi: 10.1080/1061186X.2018.1433681. Epub 2018 Feb 12.

10.

Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA.

Kang Y, Lu L, Lan J, Ding Y, Yang J, Zhang Y, Zhao Y, Zhang T, Ho RJY.

Acta Biomater. 2018 Mar 1;68:137-153. doi: 10.1016/j.actbio.2017.12.028. Epub 2017 Dec 26.

PMID:
29288085
11.

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho RJY.

J Drug Target. 2018 Jun - Jul;26(5-6):435-447. doi: 10.1080/1061186X.2017.1419363. Epub 2018 Jan 10.

12.

Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention.

Krogstad EA, Ramanathan R, Nhan C, Kraft JC, Blakney AK, Cao S, Ho RJY, Woodrow KA.

Biomaterials. 2017 Nov;144:1-16. doi: 10.1016/j.biomaterials.2017.07.034. Epub 2017 Aug 1.

13.

Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma.

Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ.

AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405.

14.

PLGA-PEG-PLGA triblock copolymeric micelles as oral drug delivery system: In vitro drug release and in vivo pharmacokinetics assessment.

Chen X, Chen J, Li B, Yang X, Zeng R, Liu Y, Li T, Ho RJY, Shao J.

J Colloid Interface Sci. 2017 Mar 15;490:542-552. doi: 10.1016/j.jcis.2016.11.089. Epub 2016 Nov 26.

PMID:
27923139
16.

ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme.

Cherry AE, Haas BR, Naydenov AV, Fung S, Xu C, Swinney K, Wagenbach M, Freeling J, Canton DA, Coy J, Horne EA, Rickman B, Vicente JJ, Scott JD, Ho RJ, Liggitt D, Wordeman L, Stella N.

Mol Cancer Ther. 2016 Sep;15(9):2018-29. doi: 10.1158/1535-7163.MCT-15-0800. Epub 2016 Jun 20.

17.

Thirty-day rat toxicity study reveals reversible liver toxicity of mifepristone (RU486) and metapristone.

Xiao Y, Zhu Y, Yu S, Yan C, Ho RJ, Liu J, Li T, Wang J, Wan L, Yang X, Xu H, Wang J, Tu X, Jia L.

Toxicol Mech Methods. 2016;26(1):36-45. doi: 10.3109/15376516.2015.1118715. Epub 2016 Feb 23.

PMID:
26907462
18.

Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ.

Nanomedicine (Lond). 2016;11(5):545-64. doi: 10.2217/nnm.16.1. Epub 2016 Feb 19. Review.

19.

Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles.

Partridge SC, Kurland BF, Liu CL, Ho RJ, Ruddell A.

Sci Rep. 2015 Oct 26;5:15641. doi: 10.1038/srep15641.

20.

Systems Approach to targeted and long-acting HIV/AIDS therapy.

Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J.

Drug Deliv Transl Res. 2015 Dec;5(6):531-9. doi: 10.1007/s13346-015-0254-y.

21.

A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.

Koehn J, Ding Y, Freeling J, Duan J, Ho RJ.

Antimicrob Agents Chemother. 2015 Nov;59(11):6682-8. doi: 10.1128/AAC.00869-15. Epub 2015 Jul 27.

22.

Synthesis, Characterization, and Anticancer Activity of Novel Lipophilic Emodin Cationic Derivatives.

Yang X, Zhao W, Hu X, Hao X, Hong F, Wang J, Xiang L, Zhu Y, Yuan Y, Ho RJ, Wang W, Shao J.

Chem Biol Drug Des. 2015 Dec;86(6):1451-7. doi: 10.1111/cbdd.12612. Epub 2015 Aug 7.

PMID:
26108260
23.

Paclitaxel improves outcome from traumatic brain injury.

Cross DJ, Garwin GG, Cline MM, Richards TL, Yarnykh V, Mourad PD, Ho RJ, Minoshima S.

Brain Res. 2015 Aug 27;1618:299-308. doi: 10.1016/j.brainres.2015.06.006. Epub 2015 Jun 15.

24.

Antiretroviral nanoparticles: the future is now: authors' response to editorial comments.

Freeling JP, Ho RJ.

AIDS. 2015 Apr 24;29(7):863-4. doi: 10.1097/QAD.0000000000000600. No abstract available.

25.

A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis.

Xiang L, Chi T, Tang Q, Yang X, Ou M, Chen X, Yu X, Chen J, Ho RJ, Shao J, Jia L.

Oncotarget. 2015 Apr 20;6(11):9295-312.

26.

pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model.

Zhang YJ, Zhan X, Wang L, Ho RJ, Sasaki T.

J Pharm Sci. 2015 May;104(5):1815-24. doi: 10.1002/jps.24407. Epub 2015 Mar 9.

27.

Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms.

Sun J, Peng Y, Wu H, Zhang X, Zhong Y, Xiao Y, Zhang F, Qi H, Shang L, Zhu J, Sun Y, Liu K, Liu J, A J, Ho RJ, Wang G.

Drug Metab Dispos. 2015 May;43(5):713-24. doi: 10.1124/dmd.114.060905. Epub 2015 Feb 13.

PMID:
25681130
28.

Two decades of publishing excellence in pharmaceutical biotechnology.

Volkin DB, Hershenson S, Ho RJ, Uchiyama S, Winter G, Carpenter JF.

J Pharm Sci. 2015 Feb;104(2):290-300. doi: 10.1002/jps.24285. Epub 2014 Dec 1. No abstract available.

29.

Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.

Freeling JP, Koehn J, Shu C, Sun J, Ho RJ.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):107-14. doi: 10.1089/aid.2014.0210.

30.

Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.

Freeling JP, Koehn J, Shu C, Sun J, Ho RJ.

AIDS. 2014 Nov 13;28(17):2625-7. doi: 10.1097/QAD.0000000000000421. Erratum in: AIDS. 2015 Aug 24;29(13):1727.

31.

Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.

Duan J, Freeling JP, Koehn J, Shu C, Ho RJ.

J Pharm Sci. 2014 Aug;103(8):2520-9. doi: 10.1002/jps.24046. Epub 2014 Jun 19.

32.
33.

Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence.

Freeling JP, Ho RJ.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2512-3. doi: 10.1073/pnas.1406554111. Epub 2014 Jun 2. No abstract available.

34.

Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma.

Koehn J, Ho RJ.

Antimicrob Agents Chemother. 2014 May;58(5):2675-80. doi: 10.1128/AAC.02748-13. Epub 2014 Feb 24.

35.
36.

Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Kraft JC, Freeling JP, Wang Z, Ho RJ.

J Pharm Sci. 2014 Jan;103(1):29-52. doi: 10.1002/jps.23773. Epub 2013 Nov 25. Review.

38.

pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members.

Zhang YJ, Gallis B, Taya M, Wang S, Ho RJ, Sasaki T.

PLoS One. 2013;8(3):e59086. doi: 10.1371/journal.pone.0059086. Epub 2013 Mar 14.

39.

Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.

Endsley AN, Ho RJ.

J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):417-24. doi: 10.1097/QAI.0b013e3182653c1f.

41.

Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells.

Endsley AN, Ho RJ.

AAPS J. 2012 Jun;14(2):225-35. doi: 10.1208/s12248-012-9329-6. Epub 2012 Mar 6.

42.

Elucidation of the time course of adenosine deaminase APOBEC3G and viral infectivity factor vif in HIV-2(287) -infected infant macaques.

Endsley AN, Ho RJ.

J Med Primatol. 2012 Feb;41(1):52-9. doi: 10.1111/j.1600-0684.2011.00518.x. Epub 2011 Oct 24.

43.

Editorial: human genome information.

Ho RJ.

J Pharm Sci. 2011 Oct;100(10):4045-6. doi: 10.1002/jps.22713. Epub 2011 Jul 20. No abstract available.

44.

Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats.

Hoekman JD, Ho RJ.

Anesth Analg. 2011 Sep;113(3):641-51. doi: 10.1213/ANE.0b013e3182239b8c. Epub 2011 Jun 27.

45.

Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects.

Ho MT, Kelly EJ, Bodor M, Bui T, Kowdley KV, Ho RJ.

Ann Hepatol. 2011 Jul-Sep;10(3):327-32.

46.

Recruitment of Chinese American elders into dementia research: the UCSF ADRC experience.

Chao SZ, Lai NB, Tse MM, Ho RJ, Kong JP, Matthews BR, Miller BL, Rosen HJ.

Gerontologist. 2011 Jun;51 Suppl 1:S125-33. doi: 10.1093/geront/gnr033.

47.

Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers.

Crouthamel MH, Kelly EJ, Ho RJ.

Transgenic Res. 2012 Feb;21(1):113-30. doi: 10.1007/s11248-011-9512-z. Epub 2011 May 3.

48.

Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

Hoekman JD, Ho RJ.

AAPS PharmSciTech. 2011 Jun;12(2):534-43. doi: 10.1208/s12249-011-9614-1. Epub 2011 Apr 26.

49.

Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.

Abbasi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O'Donnell PV, Deeg HJ, Pawlikowski MA, Ho RJ, McCune JS.

J Clin Pharmacol. 2011 Oct;51(10):1429-38. doi: 10.1177/0091270010382915. Epub 2010 Dec 6.

50.

Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes.

Ho BE, Shen DD, McCune JS, Bui T, Risler L, Yang Z, Ho RJ.

Sci Pharm. 2010 Jul-Sep;78(3):473-81. doi: 10.3797/scipharm.1002-11. Epub 2010 Jun 9.

Supplemental Content

Support Center